Story preview
Topics in this story
Continue reading on the publisher site for the full article.
Read on publisher →Pharmacy Times
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
7
in the last 3 days
First reported
34 hr. ago
6 outlets since
Countries
6 other outlets reported this story in the last 3 days.
Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.
Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.
Teva said it is debuting the drug to overcome adherence issues with an oral counterpart and improve symptom outcomes.